Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in overweight or obesity
NCT06267092Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CagriSema in obesity (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in mean postprandial appetite score based on visual analogue scale at 24 weeks. Started Feb 2024; status: completed.
02
Drugs
CagriSema
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06267092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06267092.